The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease.

Abstract excerpt

BACKGROUND: Genetic variations in the CYP2C19 gene, which encodes the major enzyme responsible for activating clopidogrel, may influence response to Clopidogrel antiplatelet therapy. This study aimed to assess the prevalence of CYP2C19 variants in Syrian patients with coronary artery disease (CAD) and evaluate the impact of these variants on the clinical efficacy of a doubled maintenance dose of clopidogrel...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Clopidogrel
• Share to Coronary Artery Disease